Melvin Chua, Head of the Department of Head Neck and Thoracic Cancers, Division of Radiation Oncology at National Cancer Centre Singapore, shared on X/Twitter:
“Interesting results from LEAP010 – combo Pembro with Levatinib or Carbozatinib. Evidently increased ORR, possibly PFS but no difference in OS
Loss of OS signal due to effective salvage regimens?”
Source: Melvin Chua/X
